Here is What Institutional Investors Think About Exact Sciences Corp (NASDAQ:EXAS)

August 29, 2017 - By Darrin Black

 Here is What Institutional Investors Think About Exact Sciences Corp (NASDAQ:EXAS)

Sentiment for Exact Sciences Corp (NASDAQ:EXAS)

Exact Sciences Corp (NASDAQ:EXAS) institutional sentiment decreased to 1.08 in Q4 2016. Its down -0.40, from 1.48 in 2016Q3. The ratio dived, as 98 funds opened new or increased positions, while 91 sold and trimmed holdings in Exact Sciences Corp. The funds in our partner’s database reported: 88.31 million shares, up from 87.34 million shares in 2016Q3. Also, the number of funds holding Exact Sciences Corp in their top 10 positions decreased from 3 to 2 for a decrease of 1. Sold All: 35 Reduced: 56 Increased: 67 New Position: 31.

Exact Sciences Corporation is a molecular diagnostics company. The company has market cap of $4.90 billion. The Firm focuses on the early detection and prevention of some forms of cancer. It currently has negative earnings. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer.

The stock increased 3.05% or $1.22 during the last trading session, reaching $41.18. About shares traded. EXACT Sciences Corporation (NASDAQ:EXAS) has risen 458.24% since August 29, 2016 and is uptrending. It has outperformed by 441.54% the S&P500.

Sanctuary Wealth Advisors Llc holds 2.88% of its portfolio in EXACT Sciences Corporation for 242,715 shares. Shannon River Fund Management Llc owns 550,000 shares or 2.29% of their US portfolio. Moreover, Thompson Investment Management Inc. has 1.57% invested in the company for 600,294 shares. The China-based J&P(China)Capital Management Co.Ltd has invested 1.54% in the stock. Zevenbergen Capital Investments Llc, a Washington-based fund reported 2.33 million shares.#img1#

Since January 1, 0001, it had 0 insider purchases, and 5 sales for $514,021 activity.

EXACT Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Ratings analysis reveals 60% of EXACT Sciences’s analysts are positive. Out of 15 Wall Street analysts rating EXACT Sciences, 9 give it “Buy”, 1 “Sell” rating, while 5 recommend “Hold”. The lowest target is $4 while the high is $5000. The stock’s average target of $30 is -27.15% below today’s ($41.18) share price. EXAS was included in 45 notes of analysts from July 24, 2015. The rating was maintained by Cowen & Co with “Buy” on Wednesday, May 31. Canaccord Genuity maintained the shares of EXAS in report on Thursday, July 20 with “Buy” rating. The rating was maintained by Jefferies on Tuesday, July 4 with “Buy”. TH Capital maintained it with “Buy” rating and $15 target in Tuesday, October 6 report. Cowen & Co maintained the shares of EXAS in report on Friday, August 4 with “Buy” rating. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) has “Buy” rating given on Wednesday, October 7 by Mizuho. The rating was downgraded by Roth Capital on Thursday, February 25 to “Neutral”. On Thursday, June 16 the stock rating was upgraded by Craig Hallum to “Buy”. On Thursday, October 1 the stock rating was initiated by Craig Hallum with “Buy”. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) has “Buy” rating given on Thursday, August 24 by Leerink Swann.

More notable recent EXACT Sciences Corporation (NASDAQ:EXAS) news were published by: Nasdaq.com which released: “Green Valley Investors Llc Buys The Kraft Heinz Co, Exact Sciences Corp, O …” on August 10, 2017, also Fool.com with their article: “Is Exact Sciences a buy?” published on August 19, 2017, Fool.com published: “Here’s Why the Best Is Yet to Come for Exact Sciences” on August 02, 2017. More interesting news about EXACT Sciences Corporation (NASDAQ:EXAS) were released by: Fool.com and their article: “The case for Exact Sciences” published on August 11, 2017 as well as Nasdaq.com‘s news article titled: “Up 187% in 2017, Is Exact Sciences Corp. Stock Still a Buy?” with publication date: August 19, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.